The gene therapy that cures “bubble boy disease” isn’t worth it to Glaxo – MIT Technology Review
MIT Technology Review |
The gene therapy that cures “bubble boy disease” isn’t worth it to Glaxo
MIT Technology Review An analyst at Goldman Sachs asked a troubling question this week about gene therapy. “Is curing patients a sustainable business model?” In social media, reactions were quick and sharp. “Cold and immoral.” “Capitalism at its finest.” But the Goldman … Lonza makes gene therapy ambitions clear with Texas plantBioPharma Dive Recon: GSK Sells Gene Therapy AssetsRegulatory Focus |
Bulletin of the Atomic Scientists |
How do we control dangerous biological research?
Bulletin of the Atomic Scientists At DARPA—the Defense Advanced Research Projects Agency, the US military’s research wing—the goal to “harness biology as technology” is one of four main areas of focus for its strategic investments. The biological sciences are expected to play a … |
|
A Call for ‘Smarter’ Immunotherapy Clinical Trials
Cancer Network Immunotherapy has ushered in a new golden age of cancer treatment. Checkpoint inhibitors have offered new hope in the battling a variety of cancers. However, only about 20% of patients who receive these agents are benefitting. It is believed combining … |